← All trials
NCT05349591
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 15, 2022
- Primary completion
- May 15, 2024
- Completion date
- May 15, 2024
- First posted
- Apr 27, 2022
- Last posted
- Sep 15, 2022
- Enrollment
- 11
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of AlbertaLead sponsor
- University of AlbertaOverall official - principal investigator
- University of AlbertaStudy director
- Juvenile Diabetes Research FoundationCollaborator
- Juvenile Diabetes Research FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.